Definium Therapeutics (DFTX) Expected to Announce Quarterly Earnings on Thursday

Definium Therapeutics (NASDAQ:DFTX) will likely be posting its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Definium Therapeutics to post earnings of ($0.48) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Definium Therapeutics Stock Performance

DFTX opened at $16.95 on Tuesday. The firm has a market cap of $1.67 billion, a PE ratio of -8.31 and a beta of 2.57. The company has a quick ratio of 3.30, a current ratio of 3.30 and a debt-to-equity ratio of 0.31. The business has a fifty day simple moving average of $15.26 and a 200-day simple moving average of $12.63. Definium Therapeutics has a fifty-two week low of $4.70 and a fifty-two week high of $18.70.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on DFTX shares. Jefferies Financial Group started coverage on Definium Therapeutics in a research report on Thursday, January 29th. They issued a “buy” rating and a $30.00 price target for the company. Chardan Capital upgraded Definium Therapeutics to a “strong-buy” rating in a report on Wednesday, November 19th. Canaccord Genuity Group raised their target price on shares of Definium Therapeutics from $16.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Robert W. Baird set a $37.00 target price on shares of Definium Therapeutics in a research report on Thursday, January 29th. Finally, JonesTrading started coverage on shares of Definium Therapeutics in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $34.20.

Insider Buying and Selling at Definium Therapeutics

In other news, insider Mark Sullivan sold 11,276 shares of the company’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $148,279.40. Following the transaction, the insider owned 282,576 shares in the company, valued at $3,715,874.40. This represents a 3.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Robert Barrow sold 25,791 shares of the firm’s stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $339,151.65. Following the sale, the chief executive officer owned 778,477 shares of the company’s stock, valued at approximately $10,236,972.55. This represents a 3.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 42,667 shares of company stock valued at $561,071 in the last 90 days. 2.26% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Definium Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Commodore Capital LP raised its holdings in shares of Definium Therapeutics by 10.5% during the second quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock worth $32,450,000 after acquiring an additional 475,000 shares in the last quarter. Vanguard Group Inc. increased its position in Definium Therapeutics by 11.0% in the 3rd quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock worth $23,732,000 after purchasing an additional 198,878 shares during the last quarter. UBS Group AG raised its stake in shares of Definium Therapeutics by 7.3% during the 3rd quarter. UBS Group AG now owns 551,809 shares of the company’s stock worth $6,506,000 after purchasing an additional 37,364 shares in the last quarter. Orbimed Advisors LLC acquired a new stake in shares of Definium Therapeutics during the 3rd quarter valued at about $4,337,000. Finally, Millennium Management LLC lifted its holdings in shares of Definium Therapeutics by 62.6% during the 3rd quarter. Millennium Management LLC now owns 298,205 shares of the company’s stock valued at $3,516,000 after buying an additional 114,805 shares during the last quarter. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.